{
    "Rank": 981,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00459121",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CDR0000539273"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA022453",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA022453"
                        },
                        {
                            "SecondaryId": "WSU-2006-122",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "Barbara Ann Karmanos Cancer Institute"
                        },
                        {
                            "SecondaryId": "WSU-011807MP2F",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "Wayne State University - Human Investigation Committee"
                        },
                        {
                            "SecondaryId": "WSU-0612004427",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "Wayne State University - Human Investigation Committee"
                        },
                        {
                            "SecondaryId": "ZENECA-IRUSZACT0029"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Barbara Ann Karmanos Cancer Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery",
                "OfficialTitle": "Assessment of Feasibility and Safety of the Addition of ZD6474 (Zactima) to Carboplatin and Paclitaxel Administered Neo-Adjuvantly in Stage IB, II and T3, N1 Non-Small Cell Lung Cancer (NSCLC)"
            },
            "StatusModule": {
                "StatusVerifiedDate": "February 2013",
                "OverallStatus": "Terminated",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "July 2007"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "January 2008",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "October 2008",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "April 9, 2007",
                "StudyFirstSubmitQCDate": "April 9, 2007",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "April 11, 2007",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "November 12, 2012",
                "ResultsFirstSubmitQCDate": "November 12, 2012",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "December 7, 2012",
                    "ResultsFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "March 13, 2019",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "March 26, 2019",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Shirish M. Gadgeel",
                    "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "Barbara Ann Karmanos Cancer Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Barbara Ann Karmanos Cancer Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vandetanib together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.\n\nPURPOSE: This phase II trial is studying how well giving vandetanib together with carboplatin and paclitaxel works in treating patients with stage I, stage II, or stage III non-small cell lung cancer that can be removed by surgery.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nDetermine the feasibility of neoadjuvant vandetanib in combination with carboplatin and paclitaxel in patients with resectable stage IB, II, or IIIA non-small cell lung cancer.\n\nSecondary\n\nAssess the 30-day postoperative mortality rate in these patients.\nAssess the toxicity of this regimen in these patients.\nDetermine the percentage of patients who complete all planned courses of therapy.\nAssess the clinical response rate in patients treated with this regimen.\nAssess the pathologic complete response rate in patients treated with this regimen.\n\nOUTLINE: This is a multicenter study.\n\nPatients receive oral vandetanib once daily on days 1-21. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 3 courses.\n\nPatients undergo surgery at least 3 weeks after the last course of chemotherapy.\n\nPROJECTED ACCRUAL: A total of 15 patients will be accrued for this study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Lung Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage I non-small cell lung cancer",
                        "stage II non-small cell lung cancer",
                        "stage IIIA non-small cell lung cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "2",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Zactima, Paclitaxel, Carboplatin",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.\n\nNeoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: carboplatin",
                                    "Drug: paclitaxel",
                                    "Drug: Zactima",
                                    "Procedure: neoadjuvant therapy"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "carboplatin",
                            "InterventionDescription": "Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Zactima, Paclitaxel, Carboplatin"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Paraplatin \u00ae"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "paclitaxel",
                            "InterventionDescription": "Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Zactima, Paclitaxel, Carboplatin"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Taxol \u00ae",
                                    "Onxal TM"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Zactima",
                            "InterventionDescription": "Zactima- 100 mg orally daily, starting on day 1 of cycle 1.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Zactima, Paclitaxel, Carboplatin"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Caprelsa",
                                    "ZD6474",
                                    "Vandetanib"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "neoadjuvant therapy",
                            "InterventionDescription": "Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Zactima, Paclitaxel, Carboplatin"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "R0 Resection"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Complete Resection (R0) Rate",
                            "PrimaryOutcomeTimeFrame": "Following three cycles of pre-operative zactima and carboplatin/paclitaxel"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Post-Operative Mortality Rate",
                            "SecondaryOutcomeTimeFrame": "at 30 days"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Assess Toxicity of This Regimen and the Percentage of Patients Completing All Planned Cycles of Therapy",
                            "SecondaryOutcomeDescription": "Serum chemistry includes Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, total protein, SGOT [AST], SGPT [ALT], sodium, laboratory tests should be done on a weekly basis for the first cycle. After the first cycle laboratory tests should be done within 72 hours of each dose of carboplatin/paclitaxel.",
                            "SecondaryOutcomeTimeFrame": "Weekly for the first cycle; Thereafter within 72 hours of each dose of carboplatin/paclitaxel"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Assess the Clinical Response Rate of the Proposed Pre-operative Regimen",
                            "SecondaryOutcomeDescription": "Patients will undergo tumor evaluation when all of the three cycles have been completed unless the treating physician has concerns regarding tumor progression. If the patient has undergone tumor evaluation prior to the last cycle the patient will require repeat tumor assessment within 4 weeks of completion of the last cycle of therapy",
                            "SecondaryOutcomeTimeFrame": "End of three cycles of treatment"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Assess the Complete Pathologic Complete Response (CR) Rate With This Regimen.",
                            "SecondaryOutcomeDescription": "Evaluation of the number of patients who have no evidence of tumor in the resected tumor.",
                            "SecondaryOutcomeTimeFrame": "30 days post surgery"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting 1 of the following staging criteria:\n\nStage IB or II disease\nT3, N0-1 disease (stage IIIA)\nDeemed a surgical candidate\nNo prior lung cancer (NSCLC or small cell lung cancer)\n\nPATIENT CHARACTERISTICS:\n\nECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%\nWBC \u2265 3,000/mm\u00b3\nAbsolute neutrophil count \u2265 1,500/mm\u00b3\nPlatelet count \u2265 100,000/mm\u00b3\nBilirubin normal\nAST and ALT \u2264 2.5 times upper limit of normal (ULN)\nCreatinine \u2264 1.5 times ULN\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nNo evidence of severe or uncontrolled systemic disease or any concurrent condition that, in the opinion of the investigator, would preclude study compliance\nNo peripheral neuropathy \u2265 grade 2\nNo hemoptysis within the past 12 weeks\nNo spontaneous bleeding within the past 12 weeks\nNo clinically significant cardiac event (e.g., NYHA class II-IV heart disease, myocardial infarction) within the past 3 months\n\nNo history of asymptomatic sustained ventricular tachycardia or arrhythmia that is symptomatic or requires treatment, including any of the following:\n\nMultifocal premature ventricular contractions\nBigeminy\nTrigeminy\nVentricular tachycardia\n\nUncontrolled atrial fibrillation\n\nAtrial fibrillation controlled with medication allowed\nNo history of QTc prolongation as a result from other medication that required discontinuation of that medication\nNo congenital long QT syndrome or first-degree family relative with an unexplained death before the age of 40\nNo left bundle branch block\n\nNo QTc with Bazett's correction that is unmeasurable or QTc \u2265 480 milliseconds on screening ECG\n\nPatients with QTc \u2265 480 milliseconds on screening ECG may have ECG repeated twice\n\nAverage QTc from the 3 screening ECG's must be < 480 milliseconds\nNo uncontrolled hypertension (systolic BP > 160 mm Hg or diastolic BP > 100 mm Hg)\nNo active diarrhea or active gastrointestinal disease that may affect the absorption of study drugs or ability to tolerate study drugs\nNo other malignancy within the past 3 years except in situ cervical carcinoma or adequately treated basal cell or squamous cell carcinoma of the skin\n\nPRIOR CONCURRENT THERAPY:\n\nMore than 4 weeks since major surgery and recovered\nNo prior carboplatin, paclitaxel, or vandetanib\nMore than 30 days since prior investigational agents\n\nMore than 2 weeks since prior and no concurrent drugs that induce CYP3A4 including, but not limited to, any of the following:\n\nRifampin\nPhenytoin\nCarbamazepine\nBarbiturates\nHypericum perforatum (St. John's wort)\nNo medication that may cause QTc prolongation or induce torsades de pointes for 2 weeks prior to beginning study treatment, during, and for 2 weeks after completion of study treatment\nNo concurrent combination antiretroviral treatment for HIV-positive patients\nNo other concurrent investigational agents",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "120 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Shirish M. Gadgeel, MD",
                            "OverallOfficialAffiliation": "Barbara Ann Karmanos Cancer Institute",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Barbara Ann Karmanos Cancer Institute",
                            "LocationCity": "Detroit",
                            "LocationState": "Michigan",
                            "LocationZip": "48201-1379",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "SeeAlsoLinkList": {
                    "SeeAlsoLink": [
                        {
                            "SeeAlsoLinkLabel": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database",
                            "SeeAlsoLinkURL": "http://cancer.gov/clinicaltrials"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowPreAssignmentDetails": "Feasibility and safety.",
                "FlowRecruitmentDetails": "Unable to enroll patients in a timely fashion. The decision was made to close the study after consulting with AstraZeneca.",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Zactima, Paclitaxel, Carboplatin",
                            "FlowGroupDescription": "Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.\n\nNeoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "2"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "2"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Zactima, Paclitaxel, Carboplatin",
                            "BaselineGroupDescription": "Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.\n\nNeoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "2"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "56.5",
                                                                "BaselineMeasurementSpread": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Complete Resection (R0) Rate",
                            "OutcomeMeasurePopulationDescription": "No analysis was completed only 2 patients enrolled, study closed due to slow accrual.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "Following three cycles of pre-operative zactima and carboplatin/paclitaxel",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Zactima+Carboplatin & Paclitaxel-assess Feasibility & Safety",
                                        "OutcomeGroupDescription": "Study closed before an evaluable number of participants could be accrued. No summary of statistics will be collected for two participants, per the statistician."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Post-Operative Mortality Rate",
                            "OutcomeMeasurePopulationDescription": "No analysis was completed only 2 patients enrolled, study closed due to slow accrual.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "at 30 days",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Zactima, Paclitaxel, Carboplatin",
                                        "OutcomeGroupDescription": "Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.\n\nNeoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Assess Toxicity of This Regimen and the Percentage of Patients Completing All Planned Cycles of Therapy",
                            "OutcomeMeasureDescription": "Serum chemistry includes Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, total protein, SGOT [AST], SGPT [ALT], sodium, laboratory tests should be done on a weekly basis for the first cycle. After the first cycle laboratory tests should be done within 72 hours of each dose of carboplatin/paclitaxel.",
                            "OutcomeMeasurePopulationDescription": "No analysis was completed only 2 patients enrolled, study closed due to slow accrual.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "Weekly for the first cycle; Thereafter within 72 hours of each dose of carboplatin/paclitaxel",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Zactima, Paclitaxel, Carboplatin",
                                        "OutcomeGroupDescription": "Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.\n\nNeoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Assess the Clinical Response Rate of the Proposed Pre-operative Regimen",
                            "OutcomeMeasureDescription": "Patients will undergo tumor evaluation when all of the three cycles have been completed unless the treating physician has concerns regarding tumor progression. If the patient has undergone tumor evaluation prior to the last cycle the patient will require repeat tumor assessment within 4 weeks of completion of the last cycle of therapy",
                            "OutcomeMeasurePopulationDescription": "No analysis was completed only 2 patients enrolled, study closed due to slow accrual.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "End of three cycles of treatment",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Zactima, Paclitaxel, Carboplatin",
                                        "OutcomeGroupDescription": "Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.\n\nNeoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Assess the Complete Pathologic Complete Response (CR) Rate With This Regimen.",
                            "OutcomeMeasureDescription": "Evaluation of the number of patients who have no evidence of tumor in the resected tumor.",
                            "OutcomeMeasurePopulationDescription": "No analysis was completed only 2 patients enrolled, study closed due to slow accrual.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "30 days post surgery",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Zactima, Paclitaxel, Carboplatin",
                                        "OutcomeGroupDescription": "Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.\n\nNeoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "0",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Zactima+Carboplatin & Paclitaxel-assess Feasibility & Safety",
                            "EventGroupDescription": "Study closed before an evaluable number of participants could be accrued. No summary of statistics will be collected for two participants, per the statistician.",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "2",
                            "EventGroupOtherNumAffected": "2",
                            "EventGroupOtherNumAtRisk": "2"
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Decreased ANC",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Cough",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Bicarbonate",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyperglycemia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Myalgia",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Decreased WBC count",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypercalcemia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Decreased hemoglobin",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Sinus tachycardia",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chills",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Diarrhea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "2"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes",
                    "AgreementRestrictiveAgreement": "No"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Shirish Gadgeel, M.D.",
                    "PointOfContactOrganization": "Barbara Ann Karmanos Cancer Institute",
                    "PointOfContactEMail": "sgadgeel@med.umich.edu",
                    "PointOfContactPhone": "313-576-8753"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000002289",
                            "ConditionMeshTerm": "Carcinoma, Non-Small-Cell Lung"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000002283",
                            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
                        },
                        {
                            "ConditionAncestorId": "D000001984",
                            "ConditionAncestorTerm": "Bronchial Neoplasms"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5236",
                            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
                            "ConditionBrowseLeafAsFound": "Non-Small Cell Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5230",
                            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4950",
                            "ConditionBrowseLeafName": "Bronchial Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000017239",
                            "InterventionMeshTerm": "Paclitaxel"
                        },
                        {
                            "InterventionMeshId": "D000016190",
                            "InterventionMeshTerm": "Carboplatin"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000972",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Phytogenic"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000050257",
                            "InterventionAncestorTerm": "Tubulin Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000050256",
                            "InterventionAncestorTerm": "Antimitotic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000050258",
                            "InterventionAncestorTerm": "Mitosis Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M18340",
                            "InterventionBrowseLeafName": "Carboplatin",
                            "InterventionBrowseLeafAsFound": "Level",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M19227",
                            "InterventionBrowseLeafName": "Paclitaxel",
                            "InterventionBrowseLeafAsFound": "Months",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M231",
                            "InterventionBrowseLeafName": "Albumin-Bound Paclitaxel",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25887",
                            "InterventionBrowseLeafName": "Tubulin Modulators",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25886",
                            "InterventionBrowseLeafName": "Antimitotic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}